Earnings Releases·Nov 12, 2026, 4:10 PM ET

LifeMD — Third Quarter 2026 Earnings Summary

Q3 2026 revenue declined 7% year-over-year to $44.6 million, while GAAP net loss narrowed to $5.2 million ($0.11/share) from $5.4 million in the prior-year period and $8.4 million in Q2 2026; Adjusted EBITDA loss improved to $0.4 million from $3.5 million in Q2 but turned negative compared to a $2.8 million profit in the prior-year period.
Full-year 2026 guidance was revised downward to revenue of $188–$191 million (previously $205.5–$212.5 million) and an Adjusted EBITDA loss of $10.6–$12.6 million (previously $6.0 million loss to breakeven), with Q4 2026 revenue guidance set at $46–$49 million and Adjusted EBITDA loss guidance of $2–$4 million.
Strategic partnerships with Novo Nordisk, Eli Lilly, and AT&T were established, active subscribers grew 13% year-over-year to 350,000, and pharmacy shipment volume surged 58.3% year-over-year.
Management prioritized efficiency and longer patient commitments over short-term growth, resulting in an 18% year-over-year decrease in selling and marketing expenses, while a $12.5 million term loan was secured post-quarter-end to replace the prior revolving credit facility.
Gross margin decreased to 82% from 85% due to a presentation change recognizing pharmacy medications on a gross revenue basis, and significant increases were noted in accounts payable ($37.7 million) and inventory ($10.3 million) compared to year-end 2025 levels.